These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 16977263)

  • 21. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.
    Bretzel RG; Nuber U; Landgraf W; Owens DR; Bradley C; Linn T
    Lancet; 2008 Mar; 371(9618):1073-84. PubMed ID: 18374840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT.
    Blair J; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes D; Gamble C
    Health Technol Assess; 2018 Aug; 22(42):1-112. PubMed ID: 30109847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glucose profiles in a type 1 diabetic patient successively treated with CSII using regular insulin, lispro and an implantable insulin pump.
    Catargi B; Breilh D; Roger P; Tabarin A
    Diabetes Metab; 2000 May; 26(3):210-4. PubMed ID: 10880895
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Special management of insulin lispro in continuous subcutaneous insulin infusion in young diabetic children: a randomized cross-over study.
    Tubiana-Rufi N; Coutant R; Bloch J; Munz-Licha G; Delcroix C; Montaud-Raguideau N; Ducrocq R; Limal JM; Czernichow P
    Horm Res; 2004; 62(6):265-71. PubMed ID: 15523183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis.
    Umpierrez GE; Latif K; Stoever J; Cuervo R; Park L; Freire AX; E Kitabchi A
    Am J Med; 2004 Sep; 117(5):291-6. PubMed ID: 15336577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes.
    Bode B; Weinstein R; Bell D; McGill J; Nadeau D; Raskin P; Davidson J; Henry R; Huang WC; Reinhardt RR
    Diabetes Care; 2002 Mar; 25(3):439-44. PubMed ID: 11874927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insulin Lispro with Continuous Subcutaneous Insulin Infusion is Safe and Effective in Patients with Type 2 Diabetes: A Randomized Crossover Trial of Insulin Lispro Versus Insulin Aspart.
    Thrasher J; Bhargava A; Rees TM; Wang T; Guzman CB; Glass LC
    Endocr Pract; 2015 Mar; 21(3):247-57. PubMed ID: 25370322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cessation of insulin infusion at night-time during CSII-therapy: comparison of regular human insulin and insulin lispro.
    Reichel A; Rietzsch H; Köhler HJ; Pfützner A; Gudat U; Schulze J
    Exp Clin Endocrinol Diabetes; 1998; 106(3):168-72. PubMed ID: 9710355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycemic control and perinatal outcomes of pregnancies complicated by type 1 diabetes: influence of continuous subcutaneous insulin infusion and lispro insulin.
    Chico A; Saigi I; García-Patterson A; Santos MD; Adelantado JM; Ginovart G; de Leiva A; Corcoy R
    Diabetes Technol Ther; 2010 Dec; 12(12):937-45. PubMed ID: 21128840
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes.
    Lin S; Chen M; Chen W; Lin K; Mu P; Zhu B; Xu W; Wang M; Weng J; Zeng L
    J Diabetes Res; 2018; 2018():2791584. PubMed ID: 30420969
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of continuous subcutaneous insulin infusion vs multiple daily insulin injection with glargine as basal insulin: an open parallel long-term study.
    Lepore G; Dodesini AR; Nosari I; Trevisan R
    Diabetes Nutr Metab; 2004 Apr; 17(2):84-9. PubMed ID: 15244099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A morning dose of insulin glargine prevents nocturnal ketosis after postprandial interruption of continuous subcutaneous insulin infusion with insulin lispro.
    Johansson UB; Wredling R; Adamson U; Lins PE
    Diabetes Metab; 2007 Dec; 33(6):469-71. PubMed ID: 18032083
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insulin requirement profiles and related factors of insulin pump therapy in patients with type 2 diabetes.
    Yang X; Deng H; Zhang X; Yang D; Yan J; Yao B; Weng J; Xu W
    Sci China Life Sci; 2019 Nov; 62(11):1506-1513. PubMed ID: 31197759
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of intensive insulin therapy by multiple daily injections and continuous subcutaneous infusion: a comparison study in type 2 diabetes with conventional insulin regimen failure.
    Berthe E; Lireux B; Coffin C; Goulet-Salmon B; Houlbert D; Boutreux S; Fradin S; Reznik Y
    Horm Metab Res; 2007 Mar; 39(3):224-9. PubMed ID: 17373639
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study.
    Raskin P; Bode BW; Marks JB; Hirsch IB; Weinstein RL; McGill JB; Peterson GE; Mudaliar SR; Reinhardt RR
    Diabetes Care; 2003 Sep; 26(9):2598-603. PubMed ID: 12941725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glycemic control with Humalog Mix25 in type 2 diabetes inadequately controlled with glyburide.
    Roach ; Koledova E; Metcalfe S; Hultman C; Milicevic Z;
    Clin Ther; 2001 Oct; 23(10):1732-44. PubMed ID: 11726007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Continuous subcutaneous insulin infusion in patients with type 2 diabetes: a cohort study to establish the relationship between glucose control and plasma oxidized low density lipoprotein.
    Megson IL; Treweeke AT; Shaw A; MacRury SM; Setford S; Frias JP; Anhalt H
    J Diabetes Sci Technol; 2015 May; 9(3):573-80. PubMed ID: 25652563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lispro is superior to regular insulin in transient intensive insulin therapy in type 2 diabetes.
    Murase Y; Yagi K; Sugihara M; Chujo D; Otsuji M; Muramoto H; Mabuchi H
    Intern Med; 2004 Sep; 43(9):779-86. PubMed ID: 15497510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human regular U-500 insulin via continuous subcutaneous insulin infusion versus multiple daily injections in adults with type 2 diabetes: The VIVID study.
    Grunberger G; Bhargava A; Ly T; Zisser H; Ilag LL; Malone J; Fan L; Zhang S; Johnson J
    Diabetes Obes Metab; 2020 Mar; 22(3):434-441. PubMed ID: 31865633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.